Clinical trials: Alport Syndrome
Alport Syndrome
Genotype-Phenotype Correlations in Patients With Alport Syndrome
Alport syndrome (AS) is caused by pathogenic variants in the type IV collagen genes COL4A3, COL4A4, and COL4A5. This study aims to enroll families and patients with a history of renal hematuria in 27 hospitals and detect these…
- Trial name
- NCT04947813
- Where
- China
- Volunteers
- 8,165 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Alport Syndrome
Urinary Biomarkers of the Progression of Alport Kidney Disease
The purpose of the study is to determine if there are certain laboratory tests that can be performed to detect substances or features in a child's urine that can be used to measure the progress of Alport kidney disease and the…
- Trial name
- NCT01705132
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Minnesota
Alport Syndrome
Effects of Dapagliflozin on Progression of Alport Syndrome
Recently, a series of large clinical trials have confirmed the cardio-renal protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors. but few patients with hereditary nephritis were included in these studies.
- Trial name
- NCT06226896
- Testing
- Dapagliflozin 10mg Tab
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Nanjing University School of Medicine
Alport Syndrome, X-Linked
Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of Hydroxychloroquine in qualified patients with Alport syndrome.
- Trial name
- CHXLAS (NCT04937907)
- Testing
- Hydroxychloroquine Sulfate 100 milligram (mg) Tab, Benazepril hydrochloride 10 milligram (mg) Tab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Children's Hospital
Alport Syndrome
Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Alport syndrome is a rare, inherited condition characterized by a combination of glomerular nephropathy progressing to kidney failure, deafness, and eye involvement.
- Trial name
- Eurbio-Alport (NCT05927467)
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Alport Syndrome
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
Alport syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5).
- Trial name
- ASSESS (NCT07211685)
- Testing
- BAY 3401016
- Where
- 58 sites in United States, Argentina and 13 more
- Volunteers
- 60 people
- Sponsor
- Bayer
Alport Syndrome
A Study of ELX-02 in Patients With Alport Syndrome
This is a Phase 2 open label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with X-linked or autosomal recessive Alport Syndrome with Col4A5 and Col4A3/4 nonsense mutation.
- Trial name
- NCT05448755
- Testing
- ELX-02
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Eloxx Pharmaceuticals, Inc.
Alport Syndrome, Focal Segmental Glomerulosclerosis
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary…
- Trial name
- NCT05267262
- Testing
- R3R01
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 43 people
- Sponsor
- River 3 Renal Corp.
Alport Syndrome, Thin Basement Membrane Disease
Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)
Alport syndrome (AS) is one of the most common monogenic kidney disorders, oftentimes leading to end-stage kidney disease (ESKD).
- Conditions
- Alport Syndrome, Thin Basement Membrane Disease, Alport Nephropathy
- Trial name
- COMBINE-ALPORT (NCT06499948)
- Testing
- Treatment with Spironolactone followed by Dapagliflozin followed by their combination, Treatment with Dapagliflozin followed by Spironolactone followed by their combination
- Where
- Romania
- Volunteers
- 12 people
- Sponsor
- Stefan Lujinschi
Alport Syndrome
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function. To assess the safety and tolerability of lademirsen (SAR339375) in participants with Alport syndrome.
- Trial name
- HERA (NCT02855268)
- Testing
- lademirsen (SAR339375)
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Genzyme, a Sanofi Company
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Alport Syndrome
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome.
- Trial name
- CARDINAL (NCT03019185)
- Testing
- Bardoxolone Methyl
- Where
- 63 sites in United States, Australia and 6 more
- Volunteers
- 187 people
- Sponsor
- Biogen
Collagen Type-4 Nephropathies
Enalapril in Collagen Type 4 Nephropathy
Background: Collagen IV-related nephropathies can lead to End Stage Renal Disease. Experimental studies have shown renin angiotensin aldosterone system blockade can reduce proteinuria and preserve renal function.
- Trial name
- NCT01465126
- Volunteers
- 19 people
- Sponsor
- University of Sao Paulo
Alport Syndrome
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
This study is a proof-of-concept trial of vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome.
- Trial name
- ALPESTRIA-1 (NCT06425055)
- Testing
- Vonafexor
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 26 people
- Sponsor
- Enyo Pharma
Chronic Kidney Failure in Children and Young Adults
Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
Recent trials have demonstrated positive renal outcomes of sodium-glucose co-transporter-2 inhibitors (SGLT2i) additive to angiotensin-converting-enzyme inhibitors (ACEis) in adult patients with diabetic and non-diabetic chronic…
- Trial name
- DOUBLE_PROTECT (NCT05944016)
- Testing
- Dapagliflozin
- Where
- 16 sites in Germany
- Volunteers
- 102 people
- Sponsor
- University Hospital Goettingen
Alport Syndrome, Thin Basement Membrane Disease
ASF Alport Patient Registry
Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US territories and outlying islands.
- Conditions
- Alport Syndrome, Thin Basement Membrane Disease, Hereditary Nephritis
- Trial name
- NCT06526741
- Testing
- Longitudinal data collection
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Alport Syndrome Foundation
Alport Nephropathy
Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.
This biomarker study is a follow-up to CPLATFRM2201. The goal of CBASICHR0005 is to collect another urine sample, interval clinical information, and an optional DNA sample from as many of the original 80 patients as possible.
- Trial name
- NCT03074357
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alport Syndrome, Metformin
Treatment With Metformin in Chinese Children With Alport Syndrome
This single-center, prospective, double-blind randomized placebo-controlled trial will evaluate the efficacy and safety of metformin in Chinese children with Alport syndrome who have received (and continue to receive)) ACEi/ARB.
- Trial name
- NCT05655728
- Testing
- Metformin
- Volunteers
- 78 people
- Sponsor
- Peking University First Hospital
Nephritis, Hereditary, Hematuria-Nephropathy-Deafness Syndrome
Biomarker for Alport Syndrome (BioAlport)
International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Alport syndrome and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s
- Trial name
- BioAlport (NCT02718027)
- Where
- 7 sites in Albania, Georgia and 5 more
- Volunteers
- 12 people
- Sponsor
- CENTOGENE GmbH Rostock
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege